Thermo Fisher Scientific (TMO) Projected to Post Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $5.11 per share and revenue of $10.23 billion for the quarter. Thermo Fisher Scientific has set its FY 2025 guidance at 23.100-23.500 EPS.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $422.43 on Tuesday. The firm has a market cap of $159.46 billion, a P/E ratio of 25.56, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a 50 day simple moving average of $495.35 and a 200 day simple moving average of $531.39. Thermo Fisher Scientific has a fifty-two week low of $409.85 and a fifty-two week high of $627.88.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Analyst Ratings Changes

A number of analysts have commented on TMO shares. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Citigroup cut their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $642.67.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 over the last three months. Insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Thermo Fisher Scientific stock. Brighton Jones LLC lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,409 shares of the medical research company’s stock after acquiring an additional 988 shares during the period. Brighton Jones LLC’s holdings in Thermo Fisher Scientific were worth $2,293,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.